Search research articles
Contact Us
Filters
Showing results (161-170 of 179) with videos related to
Page
of 18
Sort By:
Journal of the National Cancer Institute
|
October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Cancer Discovery
|
October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Brandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Breast Cancer Research and Treatment
|
July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2021
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA
|
May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Tomography (Ann Arbor, Mich.)
|
May 21, 2016
The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge
Wei Huang, Yiyi Chen, Andriy Fedorov, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 179) with videos related to
Sort By:
Page
of 18
Journal of the National Cancer Institute
|
October 11, 2025
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.
Cancer Discovery
|
October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
Brandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Breast Cancer Research and Treatment
|
July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square
|
May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2021
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, et al.
JCO Precision Oncology
|
April 3, 2025
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA
|
May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Tomography (Ann Arbor, Mich.)
|
May 21, 2016
The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge
Wei Huang, Yiyi Chen, Andriy Fedorov, et al.
Page
of 18